Fulgent Pharma has partnered with Moffitt Cancer Center to accelerate the development of personalized cancer therapies.

The collaboration grants Moffitt priority access to Fulgent's resources and know-how to expedite the advancement of Fulgent's clinical pipeline. This includes prioritizing clinical trials, enhancing patient screening, and data sharing. Together, the companies aim to develop personalized cancer treatments using Moffitt's scientific expertise and Fulgent's nanotherapeutic drug development platform.

Fulgent Pharma is a clinical-stage pharmaceutical company specializing in the development and commercialization of novel cancer therapies. The company is a subsidiary of the nanobiotechnology company Fulgent Genetics. Fulgent Pharma focuses on creating treatments through technologies such as nanoencapsulation to improve the delivery and efficacy of cancer drugs. Its pipeline includes targeted therapies for various cancers, such as breast, lung, ovarian, colon, and pancreatic.